1012 related articles for article (PubMed ID: 26767951)
21. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases.
Boros FA; Bohár Z; Vécsei L
Mutat Res Rev Mutat Res; 2018; 776():32-45. PubMed ID: 29807576
[TBL] [Abstract][Full Text] [Related]
22. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
Mazarei G; Leavitt BR
J Huntingtons Dis; 2015; 4(2):109-18. PubMed ID: 26397892
[TBL] [Abstract][Full Text] [Related]
23. Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.
Lee JM; Tan V; Lovejoy D; Braidy N; Rowe DB; Brew BJ; Guillemin GJ
Neuropharmacology; 2017 Jan; 112(Pt B):346-364. PubMed ID: 27265569
[TBL] [Abstract][Full Text] [Related]
24. The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives.
Ciapała K; Mika J; Rojewska E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681715
[TBL] [Abstract][Full Text] [Related]
25. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
[TBL] [Abstract][Full Text] [Related]
26. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
27. Elevated serum levels of kynurenine pathway metabolites in patients with Behçet disease.
Eryavuz Onmaz D; Tezcan D; Abusoglu S; Sivrikaya A; Kuzu M; Yerlikaya FH; Yilmaz S; Unlu A
Amino Acids; 2022 Jun; 54(6):877-887. PubMed ID: 35604497
[TBL] [Abstract][Full Text] [Related]
28. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
[TBL] [Abstract][Full Text] [Related]
30. Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage: Different Dynamics of Changes.
Fiedorowicz M; Choragiewicz T; Thaler S; Schuettauf F; Nowakowska D; Wojtunik K; Reibaldi M; Avitabile T; Kocki T; Turski WA; Kaminska A; Grieb P; Zrenner E; Rejdak R; Toro MD
Front Physiol; 2019; 10():1254. PubMed ID: 31632294
[TBL] [Abstract][Full Text] [Related]
31. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
Myint AM; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():304-13. PubMed ID: 24184687
[TBL] [Abstract][Full Text] [Related]
32. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
[TBL] [Abstract][Full Text] [Related]
33. Kynurenine pathway metabolic balance influences microglia activity: Targeting kynurenine monooxygenase to dampen neuroinflammation.
Garrison AM; Parrott JM; Tuñon A; Delgado J; Redus L; O'Connor JC
Psychoneuroendocrinology; 2018 Aug; 94():1-10. PubMed ID: 29734055
[TBL] [Abstract][Full Text] [Related]
34. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.
Sathyasaikumar KV; Stachowski EK; Wonodi I; Roberts RC; Rassoulpour A; McMahon RP; Schwarcz R
Schizophr Bull; 2011 Nov; 37(6):1147-56. PubMed ID: 21036897
[TBL] [Abstract][Full Text] [Related]
35. Altered kynurenine pathway metabolism and association with disease activity in patients with systemic lupus.
Eryavuz Onmaz D; Tezcan D; Yilmaz S; Onmaz M; Unlu A
Amino Acids; 2023 Dec; 55(12):1937-1947. PubMed ID: 37925676
[TBL] [Abstract][Full Text] [Related]
36. [Diagnoses and new therapeutic strategy focused on physiological alteration of tryptophan metabolism].
Mouri A; Hasegawa M; Kunisawa K; Saito K; Nabeshima T
Nihon Yakurigaku Zasshi; 2023 May; 158(3):233-237. PubMed ID: 36990795
[TBL] [Abstract][Full Text] [Related]
37. The kynurenine pathway in brain tumor pathogenesis.
Adams S; Braidy N; Bessede A; Brew BJ; Grant R; Teo C; Guillemin GJ
Cancer Res; 2012 Nov; 72(22):5649-57. PubMed ID: 23144293
[TBL] [Abstract][Full Text] [Related]
38. Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
Zarzecki MS; Cattelan Souza L; Giacomeli R; Silva MRP; Prigol M; Boeira SP; Jesse CR
Neurochem Res; 2020 Dec; 45(12):2959-2977. PubMed ID: 33040279
[TBL] [Abstract][Full Text] [Related]
39. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
40. Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.
Notarangelo FM; Pocivavsek A
Neuropharmacology; 2017 Jan; 112(Pt B):275-285. PubMed ID: 26944732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
